Skip to main content

Poietis

ApplicationPessac, FranceFounded 2014· One of 381 Application companies tracked by AMPulse

A French biotech company developing and producing human tissues using laser-assisted 4D bioprinting for pharmaceutical, cosmetic, and regenerative medicine applications.

CEO / Founder
Fabien Guillemot (Founder & CSO)
Team Size
11-50
Stage
Active
Total Funding
$9M
Latest Round
Series A
Key Investors
Nouvelle-Aquitaine Co-investissement, WiSEED, Bpifrance, Aquiti Gestion

Technology & Products

Key Products

NGB-R platform, NGB-C platform, NGB bioprinting systems, bioprinted human tissues for pharmaceutical, cosmetic, and regenerative medicine applications.

Technological Advantage

The ability to create complex, multi-layered functional tissues provides a significant advantage over traditional 2D cell cultures and extrusion-based 3D models. This leads to more predictive data for drug and cosmetic testing, reducing reliance on animal testing and accelerating product development pipelines.

Differentiation

Value Proposition

To provide more predictive and reliable in-vitro human tissue models for research and testing, while also developing bioprinted tissues for future therapeutic use in regenerative medicine.

How They Differentiate

Poietis differentiates through its high-precision laser-assisted bioprinting technology, which offers superior resolution and cell viability compared to the more common extrusion-based methods used by many competitors. Their focus on 4D bioprinting and developing complex, functional tissues for both in-vitro testing and future therapeutic applications sets them apart.

Market & Competition

Target Customers

Pharmaceutical and cosmetic companies, academic researchers, and clinical partners in regenerative medicine.

Industry Verticals

["Pharmaceuticals","Cosmetics","Biotechnology","Regenerative Medicine"]

Competitors

CELLINK, Organovo, EnvisionTEC

Growth & Milestones

Major Milestones

["2014: Company founded.","2017: Commercial launch of the Poieskin® tissue model.","2018: Raised €5M in a Series A funding round.","2018: Established key partnerships with major pharmaceutical (Servier) and chemical (BASF) companies.","2022: Installed the NGB-C bioprinter in a GMP-compliant facility at the University of Barcelona to advance towards clinical applications."]

Notable Customers

Servier, AP-HM (Assistance Publique – Hôpitaux de Marseille)

https://www.poietis.com

Why this company matters

Poietis occupies a distinctive position in the bioprinting landscape by applying laser-assisted technology rather than the more common extrusion-based methods used by competitors such as CELLINK and Organovo. Founded in 2014 and based in Pessac, France, the company focuses on producing in-vitro human tissue models that more closely replicate natural biology, aiming to reduce reliance on animal testing and improve predictive accuracy in drug and cosmetic development.

The core technology is a high-resolution laser-assisted bioprinting process that deposits cells with single-cell precision, achieving high cell viability and reproducibility. Poietis emphasizes 4D bioprinting, in which printed tissues mature and evolve over time to better mimic natural biological processes. The company's product line includes the NGB-R and NGB-C bioprinting platforms, as well as the Poieskin tissue model, which was the first commercialized bioprinted tissue of its kind.

Target customers include pharmaceutical and cosmetic companies, academic researchers, and clinical partners in regenerative medicine. Notable collaborations include partnerships with Servier, BASF, and the University of Barcelona, where an NGB-C bioprinter was installed in a GMP-compliant facility to advance toward therapeutic applications. Poietis has raised approximately $9 million from investors including Bpifrance and Nouvelle-Aquitaine Co-investissement.

The company's strategic moat lies in its proprietary laser-assisted bioprinting IP and its early commercialization of complex, multi-layered tissue models. However, the bioprinting market remains nascent, and scaling from research-grade models to therapeutic-grade implants will require regulatory clearance and clinical validation, which represent both the primary risk and the most significant upside.